Table of Content

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Antibody-Mediated Rejection (AMR): Market Overview at a Glance
5.1 Total Market Share (%) Distribution of Antibody-Mediated Rejection (AMR) in 2017
5.2 Total Market Share (%) Distribution of Antibody-Mediated Rejection (AMR) in 2030

6 Antibody-Mediated Rejection (AMR): Market Overview at a Glance
6.1 Introduction
6.2 Pathogenesis
6.3 Types of ABR
6.4 Risk Factors
6.5 Clinical features
6.6 Diagnosis

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Total cases of Antibody-Mediated Rejection (AMR) in 7MM
7.4 United States
7.4.1 Transplant Incidence cases in the United States
7.4.2 Antibody-Mediated Rejection Cases in the United States
7.5 EU5 Countries
7.6 Germany
7.6.1 Transplant Incidence cases in Germany
7.6.2 Antibody-Mediated Rejection Cases in Germany
7.7 France
7.7.1 Transplant Incidence cases in France
7.7.2 Antibody-Mediated Rejection Cases in France
7.8 Italy
7.8.1 Transplant Incidence cases in Italy
7.8.2 Antibody-Mediated Rejection Cases in Italy
7.9 Spain
7.9.1 Transplant Incidence cases in Spain
7.9.2 Antibody-Mediated Rejection Cases in Spain
7.10. UK
7.10.1 Transplant Incidence cases in the United Kingdom
7.10.2 Antibody-Mediated Rejection Cases in the United Kingdom
7.11 Japan
7.11.1 Transplant Incidence cases in Japan
7.11.2 Antibody-Mediated Rejection Cases in Japan

8 Treatment of Antibody-Mediated Rejection (AMR)

9 Unmet Needs

10 Emerging Therapies
10.1 Key Cross Competition
10.1.1 Other promising therapies
10.2 Clazakizumab: CSL Behring
10.2.1 Drug Description
10.2.2 Other Development Activities
10.2.3 Clinical Development
10.2.4 Safety and Efficacy
10.2.5 Product Profile
10.3 Imlifidase: Hansa Biopharma
10.3.1 Drug Description
10.3.2 Other Development Activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 VIB4920: Viela Bio
10.4.1 Drug Description
10.4.2 Clinical Development
10.4.3 Safety and Efficacy
10.4.4 Product Profile
10.5 Inebilizumab-cdon: Viela Bio
10.5.1 Drug Description
10.5.2 Clinical Development
10.5.3 Product Profile
10.6 Daratumumab: Janssen Biotech
10.6.1 Drug Description
10.6.2 Other Development Activities
10.6.3 Clinical Development
10.6.4 Product Profile

11 Antibody-Mediated Rejection (AMR): 7 Major Market Analysis
11.1 Key Findings
11.2 Market Size of Antibody-Mediated Rejection (AMR) in 7MM

12 Seven Major Market Outlook

13 United States Market Size
13.1 Total Market Size of Antibody-Mediated Rejection (AMR) in the United States
13.2 Total Market Size of Antibody-Mediated Rejection (AMR) by Therapies in the United States
13.3 Germany
13.3.1 Total market size of Antibody-Mediated Rejection (AMR) in Germany
13.3.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in Germany
13.4 France
13.4.1 Total market size of Antibody-Mediated Rejection (AMR) in France
13.4.2 Total Market size of Antibody-Mediated Rejection (AMR) by Therapies in France
13.5 Italy
13.5.1 Total market size of Antibody-Mediated Rejection (AMR) in Italy
13.5.2 Total Market size of Antibody-Mediated Rejection (AMR) by Therapies in Italy
13.6 Spain
13.6.1 Total Market Size of Antibody-Mediated Rejection (AMR) in Spain
13.6.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in Spain
13.7 United Kingdom
13.7.1 Total market size of Antibody-Mediated Rejection (AMR) in the United Kingdom
13.7.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in the UK
13.8 Japan
13.8.1 Total market size of Antibody-Mediated Rejection (AMR) in Japan
13.8.2 Total market size of Antibody-Mediated Rejection (AMR) by Therapies in Japan

14 Market Drivers

15 Market Barriers

16 SWOT Analysis

17 Market Access

18 Case Study
18.1 Antibody-mediated Rejection in Heart Transplantation: Case Presentation with a Review of Current International Guidelines
18.2 Eculizumab for the Treatment of Severe Antibody-mediated Rejection: A Case Report
18.3 Antibody-mediated rejection with detection of de novo donor-specific anti-human leukocyte antigen Class II antibodies 3 years after heart transplantation: A Case Report
18.4 Bortezomib against Refractory Antibody-mediated Rejection after ABO-Incompatible Living-donor Liver Transplantation: Dramatic Effect in Acute Phase?

19 KOL Views

20 Bibliography

21 Appendix
21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight



List of Figures


Figure 1: Epidemiology and Market Methodology
Figure 2: Activation of the Classical Complement Pathway in AMR in Renal Transplant Recipients
Figure 3: Complement Activation Pathway
Figure 4: Total Cases of Antibody-Mediated Rejection (AMR) in 7MM (2017-2030)
Figure 5: Transplant incidence Cases in the United States (2017-2030)
Figure 6: Antibody-Mediated Rejection Cases in the US (2017-2030)
Figure 7: Transplant incidence Cases in Germany (2017-2030)
Figure 8: Antibody-Mediated Rejection Cases in Germany (2017-2030)
Figure 9: Transplant incidence Cases in France (2017-2030)
Figure 10: Antibody-Mediated Rejection Cases in France (2017-2030)
Figure 11: Transplant incidence Cases in Italy (2017-2030)
Figure 12: Antibody-Mediated Rejection Cases in Italy (2017-2030)
Figure 13: Transplant incidence Cases in Spain (2017-2030)
Figure 14: Antibody-Mediated Rejection Cases in Spain (2017-2030)
Figure 15: Transplant incidence Cases in the United Kingdom (2017-2030)
Figure 16: Antibody-Mediated Rejection Cases in the UK (2017-2030)
Figure 17: Transplant incidence Cases in Japan (2017-2030)
Figure 18: Antibody-Mediated Rejection Cases in Japan (2017-2030)
Figure 19: Suggested Algorithm For Management of AMR
Figure 20: Unmet Needs
Figure 21: Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017-2030)
Figure 22: Market Size of Antibody-Mediated Rejection (AMR) in the US, USD Millions (2017-2030)
Figure 23: Market Size of Antibody-Mediated Rejection (AMR) in the US by therapies, USD Millions (2017-2030)
Figure 24: Market Size of Antibody-Mediated Rejection (AMR) in Germany, USD Millions (2017-2030)
Figure 25: Market Size of Antibody-Mediated Rejection (AMR) in Germany by therapies, USD Millions (2017-2030)
Figure 26: Market Size of Antibody-Mediated Rejection (AMR) in France, USD Millions (2017-2030)
Figure 27: Market Size of Antibody-Mediated Rejection (AMR) in France by therapies, USD Millions (2017-2030)
Figure 28: Market Size of Antibody-Mediated Rejection (AMR) in Italy, USD Millions (2017-2030)
Figure 29: Market Size of Antibody-Mediated Rejection (AMR) in Italy by therapies, USD Millions (2017-2030)
Figure 30: Market Size of Antibody-Mediated Rejection (AMR) in Spain, USD Millions (2017-2030)
Figure 31: Market Size of Antibody-Mediated Rejection (AMR) in Spain by therapies, USD Millions (2017-2030)
Figure 32: Market Size of Antibody-Mediated Rejection (AMR) in the UK, USD Millions (2017-2030)
Figure 33: Market Size of Antibody-Mediated Rejection (AMR) in the UK by therapies, USD Millions (2017-2030)
Figure 34: Market Size of Antibody-Mediated Rejection (AMR) in Japan, USD Millions (2017-2030)
Figure 35: Market Size of Antibody-Mediated Rejection (AMR) in Japan by therapies, USD Millions (2017-2030)
Figure 36: Market Drivers
Figure 37: Market Barriers


List of Tables


Table 1: Banff diagnostic categories
Table 2: Antibody-mediated rejection criteria
Table 3: Total cases of Antibody-Mediated Rejection (AMR) in 7MM (2017–2030)
Table 4: Transplant Incidence cases in the United States (2017–2030)
Table 5: Antibody-Mediated Rejection Cases in the US (2017–2030)
Table 6: Transplant Incidence cases in Germany (2017–2030)
Table 7: Antibody-Mediated Rejection Cases in Germany (2017–2030)
Table 8: Transplant Incidence cases in France (2017–2030)
Table 9: Antibody-Mediated Rejection Cases in France (2017–2030)
Table 10: Transplant Incidence cases in Italy (2017–2030)
Table 11: Antibody-Mediated Rejection Cases in Italy (2017–2030)
Table 12: Transplant Incidence cases in Spain (2017–2030)
Table 13: Antibody-Mediated Rejection Cases in Spain (2017–2030)
Table 14: Transplant Incidence cases in the United Kingdom (2017–2030)
Table 15: Antibody-Mediated Rejection Cases in the UK (2017–2030)
Table 16: Transplant Incidence cases in Japan (2017–2030)
Table 17: Antibody-Mediated Rejection Cases in Japan (2017–2030)
Table 18: Clazakizumab, Clinical Trial Description, 2020
Table 19: Imlifidase, Clinical Trial Description, 2020
Table 20: VIB4920, Clinical Trial Description, 2020
Table 21: Inebilizumab, Clinical Trial Description, 2020
Table 22: Daratumumab, Clinical Trial Description, 2020
Table 23: Market Size of Antibody-Mediated Rejection (AMR) in 7MM in USD Million (2017–2030)
Table 24: US Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 25: US Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 26: Market Size of Antibody-Mediated Rejection (AMR) in Germany, USD Millions (2017–2030)
Table 27: Germany Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 28: Market Size of Antibody-Mediated Rejection (AMR) associated in France, USD Millions (2017–2030)
Table 29: France Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 30: Market Size of Antibody-Mediated Rejection (AMR) in Italy, USD Millions (2017–2030)
Table 31: Italy Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 32: Market Size of Antibody-Mediated Rejection (AMR) in Spain, USD Millions (2017–2030)
Table 33: Spain Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 34: Market Size of Antibody-Mediated Rejection (AMR) in the UK, USD Millions (2017–2030)
Table 35: UK Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)
Table 36: Market Size of Antibody-Mediated Rejection (AMR) in Japan, USD Millions (2017–2030)
Table 37: Japan Market Size of Antibody-Mediated Rejection (AMR) in USD Million (2017–2030)